ORGANOIDSCIENCES

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

organoidrx.com

Country

South Korea

Exchange

KOSDAQ

Founded 2018

Organoidsciences develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers salivary glands, liver, and uterus disease areas.

Its portfolio also includes ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification, and EXPANSION, an organoid-based advanced science for innovative solutions. Founded in 2018, the company is based in Seongnam-si, South Korea.

Key Stats

52-Week Range

₩6810.00₩48500.00

BetaN/A

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.